The glimmer of opportunity behind the storm: Ali Pashazadeh talks biotech investment

Biotech finance has encountered what can arguably be termed the worst perfect storm in its history, and private investment in biopharma is in the midst of the longest drought.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, a strategic and financial advisory firm for the life sciences sector, in a conversation focused on the current ‘perfect storm’ in biotech and why the skies might not be quite as grey and foreboding as at first feared.

Pashazadeh discusses how developers, CDMOs, CROs, and all other companies involved in therapeutic development might have to adjust to this new world.

You can also listen to episode 203a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.